景津裝備(603279.SH):股東景津投資、薑桂廷、宋桂花合計減持5.9981%股份 減持完畢
格隆匯2月7日丨景津裝備(603279.SH)公佈,公司於2023年2月6日收到股東景津投資、薑桂廷、宋桂花發來的《關於減持景津裝備股份有限公司股份計劃實施完畢的吿知函》,其於2022年8月26日至2023年2月6日期間,通過大宗交易、集中競價交易方式,共計減持公司股份3459.02萬股,佔公司總股本的5.9981%。截至本公吿披露日,本次減持計劃實施完畢。
控股股東景津投資及實際控制人薑桂廷、宋桂花合計持有公司股份比例從減持計劃實施前50.9138%減少至 44.9156%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.